Xvivo Perfusion AB (publ) (STO:XVIVO)
Sweden · Delayed Price · Currency is SEK 201.00
+6.20 (3.18%)
Nov 4, 2026, 5:29 PM CET
Xvivo Perfusion AB Income Statement
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 958.65 | 812.17 | 822.42 | 597.54 | 415.29 | 258.39 | |
Revenue Growth | 17.83% | -1.25% | 37.63% | 43.89% | 60.72% | 43.66% |
Cost of Revenue | 276.35 | 212.67 | 206 | 152.43 | 118.34 | 70.11 |
Gross Profit | 682.3 | 599.49 | 616.42 | 445.11 | 296.96 | 188.28 |
Selling, General & Admin | 417.25 | 376.61 | 378.9 | 309.21 | 223.38 | 153.38 |
Research & Development | 146.63 | 130.17 | 147.77 | 135.94 | 69.34 | 54.04 |
Other Operating Expenses | -9.34 | -1.7 | -1.09 | -5.43 | -0.22 | -0.39 |
Operating Expenses | 554.54 | 505.07 | 525.58 | 439.72 | 292.5 | 207.02 |
Operating Income | 127.76 | 94.42 | 90.84 | 5.4 | 4.45 | -18.74 |
Interest Expense | - | -3.48 | -1.26 | -1.19 | -0.61 | -0.28 |
Interest & Investment Income | 88.09 | 7.88 | 17.16 | 8.85 | 2.12 | - |
Currency Exchange Gain (Loss) | -69.96 | -69.96 | 32.39 | 9.69 | 17.09 | 5.98 |
Other Non Operating Income (Expenses) | 12.39 | 12.39 | 63.04 | 72.78 | -0.49 | 19.75 |
EBT Excluding Unusual Items | 158.28 | 41.25 | 202.16 | 95.52 | 22.58 | 6.71 |
Merger & Restructuring Charges | -2.3 | -2.3 | -1.43 | - | - | - |
Gain (Loss) on Sale of Assets | -0.39 | -0.39 | -0.78 | -1 | -0.26 | -0.04 |
Pretax Income | 155.6 | 38.56 | 199.95 | 94.52 | 22.31 | 6.67 |
Income Tax Expense | 26.75 | 13.4 | 27.77 | 2.7 | 3.89 | -1.49 |
Net Income | 128.85 | 25.16 | 172.18 | 91.82 | 18.43 | 8.15 |
Net Income to Common | 128.85 | 25.16 | 172.18 | 91.82 | 18.43 | 8.15 |
Net Income Growth | 330.91% | -85.39% | 87.52% | 398.29% | 126.04% | - |
Shares Outstanding (Basic) | 31 | 31 | 31 | 30 | 30 | 29 |
Shares Outstanding (Diluted) | 32 | 32 | 32 | 30 | 30 | 29 |
Shares Change | -0.06% | -0.29% | 5.73% | 1.39% | 2.04% | 6.49% |
EPS (Basic) | 4.09 | 0.80 | 5.47 | 3.07 | 0.62 | 0.28 |
EPS (Diluted) | 4.09 | 0.80 | 5.44 | 3.07 | 0.62 | 0.28 |
EPS Growth | 332.76% | -85.31% | 77.35% | 394.72% | 121.43% | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 175.05 | 7.35 | 40.56 | 3.27 | 9.67 | -22.25 |
Free Cash Flow Per Share | 5.54 | 0.23 | 1.28 | 0.11 | 0.33 | -0.77 |
Gross Margin | 71.17% | 73.81% | 74.95% | 74.49% | 71.50% | 72.87% |
Operating Margin | 13.33% | 11.63% | 11.04% | 0.90% | 1.07% | -7.25% |
Profit Margin | 13.44% | 3.10% | 20.94% | 15.37% | 4.44% | 3.16% |
Free Cash Flow Margin | 18.26% | 0.90% | 4.93% | 0.55% | 2.33% | -8.61% |
EBITDA | 178.94 | 129.31 | 118.43 | 19.03 | 13.3 | -11.7 |
EBITDA Margin | 18.67% | 15.92% | 14.40% | 3.19% | 3.20% | -4.53% |
D&A For EBITDA | 51.18 | 34.9 | 27.59 | 13.64 | 8.85 | 7.04 |
EBIT | 127.76 | 94.42 | 90.84 | 5.4 | 4.45 | -18.74 |
EBIT Margin | 13.33% | 11.63% | 11.04% | 0.90% | 1.07% | -7.25% |
Effective Tax Rate | 17.19% | 34.74% | 13.89% | 2.86% | 17.42% | - |